PDK3

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pyruvate dehydrogenase kinase, isozyme 3
Protein PDK3 PDB 1y8n.png
PDB rendering based on 1y8n.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols PDK3 ; CMTX6; GS1-358P8.4
External IDs OMIM300906 MGI2384308 HomoloGene55897 IUPHAR: 2143 ChEMBL: 3893 GeneCards: PDK3 Gene
EC number 2.7.11.2
RNA expression pattern
PBB GE PDK3 206347 at tn.png
PBB GE PDK3 206348 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 5165 236900
Ensembl ENSG00000067992 ENSMUSG00000035232
UniProt Q15120 Q922H2
RefSeq (mRNA) NM_001142386 NM_145630
RefSeq (protein) NP_001135858 NP_663605
Location (UCSC) Chr X:
24.48 – 24.56 Mb
Chr X:
93.76 – 93.83 Mb
PubMed search [1] [2]

Pyruvate dehydrogenase lipoamide kinase isozyme 3, mitochondrial is an enzyme that in humans is encoded by the PDK3 gene.[1][2] It codes for an isozyme of pyruvate dehydrogenase kinase.The pyruvate dehydrogenase (PDH) complex is a nuclear-encoded mitochondrial multienzyme complex that catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It provides the primary link between glycolysis and the tricarboxylic acid (TCA) cycle, and thus is one of the major enzymes responsible for the regulation of glucose metabolism. The enzymatic activity of PDH is regulated by a phosphorylation/dephosphorylation cycle, and phosphorylation results in inactivation of PDH. The protein encoded by this gene is one of the four pyruvate dehydrogenase kinases that inhibits the PDH complex by phosphorylation of the E1 alpha subunit. This gene is predominantly expressed in the heart and skeletal muscles. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[2]

Structure[edit]

The structure of the PDK3/L2 complex has been elucidated, and there are several key features. When the L2 domain binds to PDK3, it induces a “cross-tail” conformation in PDK3, thereby stimulating activity. There are three crucial residues, Leu-140, Glu-170, and Glu-179, in the C-terminal domain that are crucial for this interaction.[3] Structural studies have indicated that L2 binding stimulates activity by disrupting the closed conformation, or ATP lid, to remove product inhibition.[4] The PDK3 subunits are in one of two conformations; one subunit exists as an “open” subunit, while the other subunit is “closed”. The open subunit is the configuration most crucial to the putative substrate-binding cleft, as it is where the target peptide can access the active center. The closed subunit blocks this target peptide because of a neighboring unwound alpha helix. Additionally, the ATP-binding loop in one PDK3 subunit adopts an open conformation, implying that the nucleotide loading into the active site is mediated by the inactive "pre-insertion" binding mode. This asymmetric complex represents a physiological state in which binding of a single L2-domain activates one of the PDHK subunits while inactivating another.[5] Thus, the L2-domains likely act not only as the structural anchors but also modulate the catalytic cycle of PDK3.

Function[edit]

The Pyruvate Dehydrogenase (PDH) complex must be tightly regulated due to its central role in general metabolism. Within the complex, there are three serine residues on the E1 component that are sites for phosphorylation; this phosphorylation inactivates the complex. In humans, there have been four isozymes of Pyruvate Dehydrogenase Kinase that have been shown to phosphorylate these three sites: PDK1, PDK2, PDK3, and PDK4.[6] The PDK3 protein is primarily found in the kidney, brain, and testis.[7]

Regulation[edit]

As the primary regulators of a crucial step in the central metabolic pathway, the pyruvate dehydrogenase family is tightly regulated itself by a myriad of factors. PDK3, in conjunction with PDK2 and PDK4, are primary targets of Peroxisome proliferator-activated receptor delta or beta, with PDK3 having five elements that respond to these receptors.[8]

References[edit]

  1. ^ Gudi R, Bowker-Kinley MM, Kedishvili NY, Zhao Y, Popov KM (Jan 1996). "Diversity of the pyruvate dehydrogenase kinase gene family in humans". J Biol Chem 270 (48): 28989–94. doi:10.1074/jbc.270.48.28989. PMID 7499431. 
  2. ^ a b "Entrez Gene: PDK3 pyruvate dehydrogenase kinase, isozyme 3". 
  3. ^ Tso SC, Kato M, Chuang JL, Chuang DT (Sep 2006). "Structural determinants for cross-talk between pyruvate dehydrogenase kinase 3 and lipoyl domain 2 of the human pyruvate dehydrogenase complex". The Journal of Biological Chemistry 281 (37): 27197–204. doi:10.1074/jbc.M604339200. PMID 16849321. 
  4. ^ Kato M, Chuang JL, Tso SC, Wynn RM, Chuang DT (May 2005). "Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl domain 2 of human pyruvate dehydrogenase complex". The EMBO Journal 24 (10): 1763–74. doi:10.1038/sj.emboj.7600663. PMID 15861126. 
  5. ^ Devedjiev Y, Steussy CN, Vassylyev DG (Jul 2007). "Crystal structure of an asymmetric complex of pyruvate dehydrogenase kinase 3 with lipoyl domain 2 and its biological implications". Journal of Molecular Biology 370 (3): 407–16. doi:10.1016/j.jmb.2007.04.083. PMID 17532006. 
  6. ^ Kolobova E, Tuganova A, Boulatnikov I, Popov KM (Aug 2001). "Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites". The Biochemical Journal 358 (Pt 1): 69–77. PMID 11485553. 
  7. ^ Sugden MC, Holness MJ (Jul 2002). "Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia". Current Drug Targets. Immune, Endocrine and Metabolic Disorders 2 (2): 151–65. PMID 12476789. 
  8. ^ Degenhardt T, Saramäki A, Malinen M, Rieck M, Väisänen S, Huotari A et al. (Sep 2007). "Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta". Journal of Molecular Biology 372 (2): 341–55. doi:10.1016/j.jmb.2007.06.091. PMID 17669420. 

Further reading[edit]